Home  »  Finance   »  Protalix BioTherapeutics Inc. (AMEX: PLX): Moving ...

Protalix BioTherapeutics Inc. (AMEX: PLX): Moving Toward A Higher Share Price

Protalix BioTherapeutics Inc. (AMEX:PLX) shares, rose in value on Friday, 05/13/22, with the stock price up by 3.92% to the previous day’s close as strong demand from buyers drove the stock to $1.06.

Actively observing the price movement in the last trading, the stock closed the session at $1.02, falling within a range of $1.01 and $1.09. The value of beta (5-year monthly) was 2.36. Referring to stock’s 52-week performance, its high was $3.08, and the low was $0.70. On the whole, PLX has fluctuated by -20.90% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Protalix BioTherapeutics Inc. currently standing at about $48.29 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 28, 2022 – Apr 01, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.11, which is expected to increase to $0 for fiscal year -$0.59 and then to about -$0.5 by fiscal year 2022. Data indicates that the EPS growth is expected to be -168.20% in 2022, while the next year’s EPS growth is forecast to be 15.30%.

Analysts have estimated the company’s revenue for the quarter at $7.79 million, with a low estimate of $7.79 million and a high estimate of $7.79 million. According to the average forecast, sales growth in current quarter could jump down -60.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $37.59 million, representing a decrease of -40.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PLX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a Hold.

1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 1 recommend it as a Buy and 0 called the PLX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PLX currently trading nearly -8.93% and -6.06% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.70, while the 7-day volatility ratio is showing 6.68% which for the 30-day chart, stands at 6.91%. Furthermore, Protalix BioTherapeutics Inc. (PLX)’s average true range (ATR) is 0.09. The company’s stock has been forecasted to trade at an average price of $11.00 over the course of the next 52 weeks, with a low of $11.00 and a high of $11.00. Based on these price targets, the low is -937.74% off current price, whereas the price has to move -937.74% to reach the yearly target high. Additionally, analysts’ median price of $11.00 is likely to be welcomed by investors because it represents a decrease of -937.74% from the current levels.

Data on historical trading for Protalix BioTherapeutics Inc. (AMEX:PLX) indicates that the trading volumes over the past 10 days have averaged 0.41 million and over the past 3 months, they’ve averaged 3.85 million. According to company’s latest data on outstanding shares, there are 45.56 million shares outstanding.

Nearly 17.88% of Protalix BioTherapeutics Inc.’s shares belong to company insiders and institutional investors own 8.40% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.58 million shares as on Jan 30, 2022, resulting in a short ratio of 12.87. According to the data, the short interest in Protalix BioTherapeutics Inc. (PLX) stood at 10.06% of shares outstanding as of Jan 30, 2022; the number of short shares registered in Dec 30, 2021 reached 4.56 million. The stock has risen by 27.45% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PLX stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam